levodopa has been researched along with lazabemide in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (69.23) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernandes, MH; Pestana, M; Soares-da-Silva, P | 1 |
| Da Prada, M | 1 |
| Fernandes, MH; Soares-da-Silva, P | 1 |
| Pestana, M; Soares-da-Silva, P | 1 |
| Fernandes, MH; Soares-da-Silva, P; Vieira-Coelho, MA | 1 |
| Abercrombie, ED; Wachtel, SR | 1 |
| Fukuda, T; Nomoto, M | 1 |
| d'Agostini, F; Damsma, G; DaPrada, M; DeBoer, P; Heeringa, MJ | 1 |
| Counsell, CE; Ives, N; Macleod, AD; Stowe, R | 1 |
| Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M | 1 |
| Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C | 1 |
| Hoon, M; Petzer, A; Petzer, JP; Viljoen, F | 1 |
3 review(s) available for levodopa and lazabemide
| Article | Year |
|---|---|
New approaches to the treatment of age-related brain disorders.
Topics: Aging; Alzheimer Disease; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Picolinic Acids; Tolcapone | 1991 |
Monoamine oxidase B inhibitors for early Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Selegiline | 2005 |
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes | 2017 |
1 trial(s) available for levodopa and lazabemide
| Article | Year |
|---|---|
A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids | 1994 |
9 other study(ies) available for levodopa and lazabemide
| Article | Year |
|---|---|
Deamination of newly-formed dopamine in rat renal tissues.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Deamination; Dopamine; In Vitro Techniques; Kidney; Levodopa; Male; Pargyline; Picolinic Acids; Rats; Rats, Wistar; Thiazoles | 1991 |
Role of monoamine oxidase A and B in the deamination of newly-formed dopamine in the rat kidney.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Deamination; Dopamine; In Vitro Techniques; Kidney; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Picolinic Acids; Rats; Rats, Inbred Strains; Thiazoles | 1990 |
Effect of type A and B monoamine oxidase selective inhibition by Ro 41-1049 and Ro 19-6327 on dopamine outflow in rat kidney slices.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Dopamine; In Vitro Techniques; Isoenzymes; Kidney Cortex; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Picolinic Acids; Rats; Rats, Wistar; Thiazoles | 1994 |
In vivo effects of the monoamine oxidase inhibitors Ro 41-1049 and Ro 19-6327 on the production and fate of renal dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Kidney; Levodopa; Male; Monoamine Oxidase Inhibitors; Picolinic Acids; Rats; Rats, Wistar; Thiazoles; Tissue Distribution | 1994 |
L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Levodopa; Male; Monoamine Oxidase Inhibitors; Nerve Endings; Oxidopamine; Picolinic Acids; Rats; Rats, Sprague-Dawley; Selegiline | 1994 |
A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Callithrix; Dialysis; Drug Interactions; Female; Levodopa; Locomotion; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Picolinic Acids | 1993 |
Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.
Topics: Animals; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Levodopa; Male; Monoamine Oxidase Inhibitors; Motor Activity; Nitrophenols; Oxidopamine; Picolinic Acids; Rats; Rotation; Thiazoles; Tolcapone | 1997 |
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Fear; In Vitro Techniques; Levodopa; Male; Maze Learning; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Pain Measurement; Parkinson Disease, Secondary; Picolinic Acids; Psychomotor Performance; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Tandem Mass Spectrometry; Time Factors | 2011 |
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biological Availability; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; HeLa Cells; Humans; Levodopa; Male; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Permeability; Picolinic Acids; Prodrugs; Solubility; Structure-Activity Relationship | 2017 |